Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
With a clutch of key data and planned regulatory applications this year from Avidity Biosciences, REGENXBIO and Capricor ...
Regenxbio advances RGX-314 and RGX-202 pipelines for AMD and Duchenne while navigating recent FDA program setbacks. Read why ...
Solid Biosciences Inc. is a Strong Buy driven by positive FDA alignment on phase 3 IMPACT DUCHENNE trial for SGT-003. Read ...
3d
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
We were honored to receive the 2025 Clinical Trials Arena R&D Excellence Award in the Precision Endocrine Therapy category, reflecting growing awareness of the utility of (Z)-endoxifen across oncology ...
By leveraging digital tools, Besmile empowers clinicians like Professor Sorensen to confidently plan and execute complex ...
Convergent Dental, the power behind the Solea® All-Tissue Dental Laser, today announced the appointment of German O. Gallucci ...
Satellos Bioscience Inc. ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving ...
Teeth grinding isn’t just a dental problem. It may also speed up aging. Research shows that people who grind their teeth ...
Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the ...
PTC Therapeutics withdrew its New Drug Application (NDA) resubmission for Translarna (ataluren) in nonsense mutation Duchenne muscular dystrophy (nmDMD) following feedback from FDA indicating that the ...
Asianet Newsable on MSN
Why MSLE stock gave up all Nasdaq debut gains and fell 8% after hours
SAT-3247, an oral therapy aimed at restoring muscle repair, is now in Phase 2 testing in children with DMD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results